Biotechnology - Molecular Partners

Filter

Current filters:

Molecular Partners

Popular Filters

73 to 97 of 2111 results

Australian regulator finds no definite melanoma link for natalizumab

Australian regulator finds no definite melanoma link for natalizumab

18-03-2014

Australia’s Therapeutic Goods Administration revealed today that it is monitoring reports of melanoma…

Asia-PacificAustraliaBiogen IdecBiotechnologyNatalizumabNeurologicalRegulationTysabri

ThromboGenics announces 2013 growth thanks to Jetrea sales

ThromboGenics announces 2013 growth thanks to Jetrea sales

18-03-2014

Belgium-based biopharma firm ThromboGenics has released its financial results for the full year 2013,…

BelgiumBiotechnologyFinancialJetreaOphthalmicsThromboGenics

More positive Ph III data for Amgen’s evolocumab

More positive Ph III data for Amgen’s evolocumab

17-03-2014

Leading independent biotech firm Amgen has released more positive clinical trial data with its cholesterol…

AmgenBiotechnologyCardio-vascularevolocumabRare diseasesResearch

Actelion says COMPASS-2 bosentan study fails primary endpoint

Actelion says COMPASS-2 bosentan study fails primary endpoint

17-03-2014

Europe’s largest biotech company Actelion has announced disappointing results of COMPASS-2, a Phase…

ActelionBiotechnologybosentanPfizerResearchRespiratory and PulmonarysildenafilTracleer

Intrexon acquires operations from Codexis and expands presence to Europe

17-03-2014

US synthetic biology firm Intrexon has acquired state-of-the-art laboratory operations in Budapest, Hungary,…

BiotechnologyCodexisEastern EuropeIntrexonMergers & AcquisitionsProduction

Six-year follow-up data from Glybera treated patients

Six-year follow-up data from Glybera treated patients

17-03-2014

Netherlands-based human gene company uniQure and privately-held Italian drugmaker Chiesi Farmaceutici…

BiotechnologyChiesi FarmaceuticiGlyberaRare diseasesResearchuniQure

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

17-03-2014

French biotech firm TxCell SA and privately-held Switzerland-headquartered Ferring International have…

BiotechnologyFerring PharmaceuticalsFinancialGastro-intestinalsLicensingOvaSaveTxCell

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

16-03-2014

Leading independent biotech firm Amgen says that findings from a pre-specified retrospective analysis…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

AnaptysBio and Tesaro team up in $340 million oncology deal

14-03-2014

Therapeutic antibody discoverer AnaptysBio announced a strategic immuno-oncology collaboration with fellow…

AnaptysBioBiotechnologyImmunologicalsLicensingOncologyTesaro

US Court upholds damages award in Actelion/Asahi litigation

14-03-2014

Switzerland-based Actelion says that the California Supreme Court has denied the firm’ petition for…

ActelionAsahi KaseiBiotechnologyfasudilFinancialLegalNorth AmericaRespiratory and PulmonaryUSA

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

14-03-2014

US drugmaker Idenix Pharmaceuticals says it has filed patent infringement law suits against biotech firm…

Anti-viralsBiotechnologyGilead SciencesIdenix PharmaceuticalsLegalNorthern EuropePatentssofosbuvirSovaldi

Galapagos sells service operations to Charles River for up to 34 million euros

Galapagos sells service operations to Charles River for up to 34 million euros

14-03-2014

Belgian biotech firm Galapagos has signed a definitive agreement to sell the BioFocus and Argenta service…

ArgentaBiotechnologyCharles River LaboratoriesGalapagosMergers & Acquisitions

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

Taiwan’s TaiGen Biotech receives domestic marketing approval for Taigexyn

13-03-2014

Taiwan-based drug developer TaiGen Biotechnology says that the Taiwan Food and Drug Administration has…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyRegulationTaiGen BiotechTaigexyn

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

13-03-2014

US biotech firm Islet Sciences says it has signed a binding letter of intent to acquire Brighthaven Ventures…

BiotechnologyDiabetesIslet SciencesMergers & AcquisitionsNephrology and Hepatologyremogliflozin

OXiGENE leaps on increased survival results for Zybrestat

OXiGENE leaps on increased survival results for Zybrestat

12-03-2014

Shares of US biotech firm OXiGENE rocketed 88.8% to $4.59 after the company announced positive results…

BiotechnologyOncologyOXiGENEResearchZybrestat

Geron nosedives on FDA clinical hold for blood disorders drug imetelstat

Geron nosedives on FDA clinical hold for blood disorders drug imetelstat

12-03-2014

USA-based Geron Corp saw its shares plunge 59% to $1.79 when the company revealed that it had received…

BiotechnologyGeron CorpimetelstatNorth AmericaOncologyRegulationResearchUSA

Sustainability of sky-high M&A valuations will be the biggest question for 2014, says new report

12-03-2014

The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Marina Biotech to use its therapeutics platform to develop drugs for rare diseases

11-03-2014

US RNAi-based drug discover Marina Biotech says that it plans to broadly apply its RNAi, antisense and…

BiotechnologyFinancialMarina BiotechRare diseasesResearch

UK’s BIA finds government unwilling to set price cap for orphan disease treatment

UK’s BIA finds government unwilling to set price cap for orphan disease treatment

11-03-2014

The majority of Members of Parliament in the UK believe there should not be a maximum price per patient…

BiotechnologyPoliticsPricingRare diseasesUK

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

France Biotech pledges to increase partnering with big pharma in 2014 plan

France Biotech pledges to increase partnering with big pharma in 2014 plan

11-03-2014

Trade body France Biotech has outlined its priorities for 2014 with a focus on innovation and removing…

BiotechnologyFinancialFrancePolitics

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

Biotie invests in Alzheimer’s drug SYN120 as it drops epilepsy pathway

11-03-2014

Finland-based Biotie Therapies (Nasdaq OMX: BTH1V), which is focused on neurodegenerative and psychiatric…

BiotechnologyBiotie TherapiesFinancialFinlandHealthcareNeurologicalNRL-1SYN120

73 to 97 of 2111 results

Company Spotlight

Fibrotech

Fibrotech

Back to top